199 related articles for article (PubMed ID: 28905539)
1. New Treatment Modalities for Geographic Atrophy.
Kandasamy R; Wickremasinghe S; Guymer R
Asia Pac J Ophthalmol (Phila); 2017; 6(6):508-513. PubMed ID: 28905539
[TBL] [Abstract][Full Text] [Related]
2. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
3. Age-related macular degeneration therapy: a review.
Ammar MJ; Hsu J; Chiang A; Ho AC; Regillo CD
Curr Opin Ophthalmol; 2020 May; 31(3):215-221. PubMed ID: 32205470
[TBL] [Abstract][Full Text] [Related]
4. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
5. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
[TBL] [Abstract][Full Text] [Related]
6. Treatment of dry age-related macular degeneration: A review.
Girgis S; Lee LR
Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
8. [Therapy approaches for geographic atrophy].
Schmitz-Valckenberg S; Mössner A; Fleckenstein M; Wiedemann P; Holz FG
Ophthalmologe; 2010 Nov; 107(11):1016-9. PubMed ID: 21088950
[TBL] [Abstract][Full Text] [Related]
9. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
10. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
Liao DS; Metlapally R; Joshi P
Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
[TBL] [Abstract][Full Text] [Related]
11. Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.
Dinah C; Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ
BMJ Open; 2024 Jan; 14(1):e075713. PubMed ID: 38238063
[TBL] [Abstract][Full Text] [Related]
12. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments for geographic atrophy in age-related macular degeneration.
Mahmoudzadeh R; Hinkle JW; Hsu J; Garg SJ
Curr Opin Ophthalmol; 2021 May; 32(3):294-300. PubMed ID: 33630787
[TBL] [Abstract][Full Text] [Related]
14. Update on geographic atrophy in age-related macular degeneration.
Biarnés M; Monés J; Alonso J; Arias L
Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
[TBL] [Abstract][Full Text] [Related]
15. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
[TBL] [Abstract][Full Text] [Related]
16. Dry age-related macular degeneration: recent progress of therapeutic approaches.
Kuno N; Fujii S
Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
[TBL] [Abstract][Full Text] [Related]
17. The Use of Neuroprotective Agents in Treating Geographic Atrophy.
Scholl HPN; Boyer D; Giani A; Chong V
Ophthalmic Res; 2021; 64(6):888-902. PubMed ID: 34153966
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR; Lawrenson JG
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD000254. PubMed ID: 28756618
[TBL] [Abstract][Full Text] [Related]
19. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
20. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.
Li H; Chintalapudi SR; Jablonski MM
Expert Opin Investig Drugs; 2017 Oct; 26(10):1103-1114. PubMed ID: 28816076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
